Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Aug;57(8):2055-60.
doi: 10.2337/db08-0184. Epub 2008 May 5.

The human lipodystrophy gene BSCL2/seipin may be essential for normal adipocyte differentiation

Affiliations

The human lipodystrophy gene BSCL2/seipin may be essential for normal adipocyte differentiation

Victoria A Payne et al. Diabetes. 2008 Aug.

Abstract

Objective: Berardinelli-Seip congenital lipodystrophy type 2 (BSCL2) is a recessive disorder featuring near complete absence of adipose tissue. Remarkably, although the causative gene, BSCL2, has been known for several years, its molecular function and its role in adipose tissue development have not been elucidated. Therefore, we examined whether BSCL2 is involved in the regulation of adipocyte differentiation and the mechanism whereby pathogenic mutations in BSCL2 cause lipodystrophy.

Research design and methods: Following the characterization of BSCL2 expression in developing adipocytes, C3H10T1/2 mesenchymal stem cells were generated in which BSCL2 expression was knocked down using short hairpin RNA (shRNA). These cells were used to investigate whether BSCL2 is required for adipogenesis. BSCL2 constructs harboring pathogenic mutations known to cause lipodystrophy were also generated and characterized.

Results: BSCL2 expression was strongly induced during adipocyte differentiation, and the induction of BSCL2 expression was essential for adipogenesis to occur. The initial induction of key adipogenic transcription factors, including peroxisome proliferator-activated receptor (PPAR)gamma and CAAT/enhancer-binding protein-alpha, was preserved in cells lacking BSCL2. However, the expression of these critical factors was not sustained, suggesting that the activity of PPARgamma was impaired. Moreover, expression of key genes mediating triglyceride synthesis, including AGPAT2, lipin 1, and DGAT2, was persistently reduced and lipid accumulation was inhibited. Analysis of pathogenic missense mutants of BSCL2 revealed that the amino acid substitution A212P causes aberrant targeting of BSCL2 within the cell, suggesting that subcellular localization of BSCL2 may be critical to its function.

Conclusions: This study demonstrates that BSCL2 is an essential, cell-autonomous regulator of adipogenesis.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
BSCL2 expression in adipose tissue and developing and mature adipocytes. A: BSCL2 mRNA expression was determined by real-time PCR in subcutaneous (scW) and epididymal (epW) white adipose tissue, brown adipose tissue (BAT), brain (Brn), skeletal muscle (SkM), heart (Hrt), liver (Lvr), kidney (Kdy), lung (Lng), and spleen (Spln) isolated from 6-week-old male mice. Data are normalized to 18S RNA and represent the means ± SEM (n = 4). BSCL2 mRNA expression was assayed by real-time PCR in differentiating cultures of murine embryonic stem cell embryoid bodies (B), C3H10T1/2 cells (C), and murine (D) or human (E) preadipocytes isolated from the stromovascular fraction of adipose tissue. Data represents means ± SEM of four (B), three (C), or six (E) independent experiments. In D, data are means ± SD obtained in two time courses with cells pooled from three mice in each case. *Statistically significant difference from values at day 0 (P < 0.05). BSCL2 mRNA expression was also determined in mature adipocyte (MAd) and stromovascular (SV) fractions from collagenase-digested mouse (F) or human (G) adipose tissue. Data are means ± SEM from 5 mice (F) and 11 individuals (G). *Significant difference vs. expression in mature adipocyte fraction (P < 0.05). H: C3H10T1/2 cells stably transfected with myc-tagged wild-type BSCL2 were induced to differentiate for 6 days, permeablized with 0.05% saponin, and then fixed and immunostained with anti-myc (BSCL2) and anti-calnexin antibodies. Merged image shows overlay of the two proteins in which yellow indicates colocalization. White arrows indicate areas of colocalization, and the inset shows a close-up of one such area. Scale bar = 20 μm. (Please see http://dx.doi.org/10.2337/db08-0184 for a high-quality digital representation of this figure.)
FIG. 2.
FIG. 2.
Effect of BSCL2 knockdown on adipogenesis in C3H10T1/2 pluripotent stem cells. A: BSCL2 mRNA was assayed by real-time PCR in C3H10T1/2 cells stably infected with a retrovirus generated with control shRNA vector (black bars) or BSCL2 targetting shRNA1 (dark gray bars) or shRNA2 (light gray bars). Values are normalized to cyclophilin A expression. Data are means ± SEM (n = 4). *Statistically significant difference vs. control cells at the same time point. B: Control cells or cells expressing BSCL2 targetting shRNA1 or shRNA2 were differentiated for 8 days, and lipid accumulation was assessed by oil red O (upper panel) and light microscopy (lower panel). Expression of mRNA encoding adipocyte transcription factors (C) and mature adipocyte marker proteins (D) was assayed by real-time PCR in control cells at day 0 (white bars) and following differentiation for 8 days in control cells (black bars) or cells expressing BSCL2 targetting shRNA1 (dark gray bars) or shRNA2 (light gray bars). Values are normalized to cyclophilin A expression. Data are means ± SEM (n = 4). *Statistically significant difference vs. control cells at day 8 (black bars). (Please see http://dx.doi.org/10.2337/db08-0184 for a high-quality digital representation of this figure.)
FIG. 3.
FIG. 3.
BSCL2 knockdown does not inhibit the induction of C/EBPβ, C/EBPδ C/EBPα, or PPARγ but inhibits SREBP1c and lipogenic gene expression during early adipogenesis in C3H10T1/2 stem cells. Control cells (black bars) or cells expressing BSCL2 targetting shRNA1 (dark gray bars) or shRNA2 (light gray bars) were induced to differentiate for various times, and the expression of mRNA encoding C/EBPβ (A) and C/EBPδ (B) was determined by real-time PCR. Data are means ± SEM (n = 4). *Statistically significant difference vs. control cells at the same time point. C: Control cells (c) or cells expressing BSCL2 targetting shRNA1 (1) or shRNA2 (2) were differentiated for various times and lysed, and samples were Western blotted to determine the expression of C/EBPβ, C/EBPδ, ETO, and calnexin as indicated. Control cells (black bars) or cells expressing BSCL2 targetting shRNA1 (dark gray bars) or shRNA2 (light gray bars) were induced to differentiate, and the expression of mRNA encoding C/EBPα (D), PPARγ2 (E), SREBP1c (F), AGPAT2 (G), DGAT2 (H), and lipin 1β (I) was determined by real-time PCR. Data are means ± SEM (n = 4). *Statistically significant difference vs. control cells at the same time point. Data were normalized to cyclophilin A mRNA expression.
FIG. 4.
FIG. 4.
Analysis of naturally occurring pathogenic mutants of BSCL2. A: Murine C3H10T1/2 pluripotent cells were transfected with empty vector (mock), myc-tagged wild-type human BSCL2 (WT), or myc-tagged wild-type human BSCL2 prematurely truncated at amino acid R275 (R275X) or bearing a point mutation causing amino acid substitution A212P. RNA was isolated 2 days posttransfection, DNase digested, and reverse transcribed before determination of human BSCL2 mRNA expression. Data are means ± SEM normalized to cyclophilin A mRNA expression (n = 3). B: mock-transfected (m) cells or cells transfected with wild-type (W), R275X (X), or A212P (P) BSCL2 were lysed and samples Western blotted with an anti-myc antibody. C: Murine C3H10T1/2 cells were transfected with myc-tagged wild-type human BSCL2 (BSCL2-WT) or myc-tagged human BSCL2 A212P (BSCL2-A212P). Cells were fixed and immunostained with anti-myc antibodies. Scale bar = 20 μm. (Please see http://dx.doi.org/10.2337/db08-0184 for a high-quality digital representation of this figure.).

Similar articles

Cited by

References

    1. Agarwal AK, Garg A: Genetic disorders of adipose tissue development, differentiation, and death. Annu Rev Genomics Hum Genet 7: 175–199, 2006 - PubMed
    1. Boguslavsky RL, Stewart CL, Worman HJ: Nuclear lamin A inhibits adipocyte differentiation: implications for Dunnigan-type familial partial lipodystrophy. Hum Mol Genet 15: 653–663, 2006 - PubMed
    1. Agarwal AK, Simha V, Oral EA, Moran SA, Gorden P, O'Rahilly S, Zaidi Z, Gurakan F, Arslanian SA, Klar A, Ricker A, White NH, Bindl L, Herbst K, Kennel K, Patel SB, Al-Gazali L, Garg A: Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. J Clin Endocrinol Metab 88: 4840–4847, 2003 - PubMed
    1. Magre J, Delepine M, Khallouf E, Gedde-Dahl T, Jr, Van Maldergem L, Sobel E, Papp J, Meier M, Megarbane A, Bachy A, Verloes A, d'Abronzo FH, Seemanova E, Assan R, Baudic N, Bourut C, Czernichow P, Huet F, Grigorescu F, de Kerdanet M, Lacombe D, Labrune P, Lanza M, Loret H, Matsuda F, Navarro J, Nivelon-Chevalier A, Polak M, Robert JJ, Tric P, Tubiana-Rufi N, Vigouroux C, Weissenbach J, Savasta S, Maassen JA, Trygstad O, Bogalho P, Freitas P, Medina JL, Bonnicci F, Joffe BI, Loyson G, Panz VR, Raal FJ, O'Rahilly S, Stephenson T, Kahn CR, Lathrop M, Capeau J: Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet 28: 365–370, 2001 - PubMed
    1. Agarwal AK, Garg A: Seipin: a mysterious protein. Trends Mol Med 10: 440–444, 2004 - PubMed

Publication types

MeSH terms